Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Pacira Pharmaceuticals, Inc. (PCRX - Snapshot Report) recently announced the pricing of its private offering of 3.25% convertible senior notes due Feb 1, 2019 worth $110 million. The offering is expected to close on Jan 23, 2013. Initial buyers will have a 30-day option of buying additional notes worth $10 million.

The senior unsecured notes can be converted into cash up to the principal amount and the remaining conversion value can be converted into cash and/or equity shares, as considered fit by the company.

Pacira said that the initial conversion rate for the notes will be 40.2945 shares of common stock per $1,000 principal amount. This is equivalent to an initial conversion price of about $24.82 per share and represents a 32.5% premium to the closing price of the stock on Jan 16, 2013.  The notes will accrue interest payable semiannually in arrears.

Pacira laid out its plans for the utilization of $105.7 million of net funds that will be raised. About $30 million of the net proceeds will be used for the repayment of all outstanding debt under its senior secured credit facility. At the end of the third quarter of 2012, Pacira had outstanding long-term debt of $24.9 million. On May 10, 2012, Oxford Finance had provided Pacira with a $27.5 million senior secured term loan.

The balance of the net proceeds from the offering will be used for the commercialization of Exparel, additional development of Exparel and general corporate purposes. Exparel is indicated for administration into the surgical site to produce postsurgical analgesia.

Exparel gained US Food and Drug Administration (FDA) approval in Oct 2011 and was launched in Apr 2012. In the third quarter of 2012, Exparel revenues were $4.6 million, accounting for 54.1% of total revenues. Pacira is trying to expand Exparel’s label for additional indications like ileostomy reversal, open and laparoscopic colectomy procedures, as well as a wide range of plastic surgery usage and TAP (Transverse Abdominis Plane) infiltration.

We currently have a Neutral recommendation on Pacira. The stock carries a Zacks Rank #3 (Hold). Right now, Valeant Pharmaceuticals International, Inc. ((VRX - Snapshot Report)) looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%